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COST AND SURVIVAL ANALYSIS OF TREATING STAGE IV 
 
NON -SMALL CELL LUNG CANCER 
 
EDMUND FOLEFAC 
 
ABSTRACT 
 
The United States spends about 17% of its gross domestic product (GDP) on healthcare, 
the most of any industrialized nation. Oncology care alone accounts for 5–10% of this 
expenditure. Although the cancer survival data in the US are better than of most 
industrialized nations, the fact that healthcare expenditure is rising faster than the GDP 
makes the current situation unsustainable.  In 2010 lung cancer accounted for 13% of the 
124 billion dollars the USA spent on cancer care. Though survival for some patients with 
metastatic non-small cell lung cancer is improving with increasing use of targeted 
therapy, for the majority of patients it is still short but the amount of money spent treating 
them is quit high. With many different chemotherapy regimens to choose from, different 
threshold for individual clinicians to initiate and discontinue therapy as well as the lack of 
firm guidelines to image patients during treatment, we decided to study the cost and cost 
distribution of treating this patient population at our institution with the goal of 
identifying areas of waste reduction and improve efficiency.  
Methods 
We searched the BMC cancer database for all stage IV non-small cell lung cancer 
patients treated between 2006 and 2011.  Information such as demographics, number of 
clinic visits, days spent in the hospital (both inpatients and ER visits), types of 
chemotherapy each patient received, number of CT, MRI, PET and bone scans were 
	  	   vii 
extracted from the medical records. The date of death for each patient was identified 
through the Social Security Administration’s Death Master File as well as genealogy 
bank and ancestry websites. The costs of inpatient stay and ER visits, imaging and 
pathology were obtained from the appropriate hospital authorities. The costs of 
chemotherapy (medications) were obtained from the oncology pharmacy while the cost 
of outpatient labs, chemotherapy administration and charges for services provided by the 
outpatient clinic staff was obtained from the clinic billing office. 
Results 
Between the study period, 224 patients were treated at BMC for metastatic non-small cell 
lung cancer.  Of the patients in the study, 57% were whites, 9% were homeless, 43% 
received chemotherapy. The median survival was 5 months for patients not treated with 
chemotherapy, 8 months for patients treated with cytotoxic chemotherapy alone and 9.2 
months for patients who received targeted therapy as part of their treatment. The mean 
charge for   treatment was $127,000; ranging from $78,000 for patients not treated with 
chemo to $259,000 for those who received biologic. The charges per month of survival 
were between $28,000 and $32,000.  The charges per month of survival were on average 
$12,000 less for white patients and $15,000 more for homeless patient. Inpatient 
treatment accounted for 56% of the charges, imaging 15% and outpatient including 
chemo 18%. 
Conclusion 
Metastatic non- small cell lung cancer is expensive to treat with a bulk of the expenditure 
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in the inpatient setting. Imaging is also responsible for a significant percentage of the 
expenditure. Significant cost reduction can be made without negatively impacting patient 
survival if we can find a way of reducing inpatient hospital stay and imaging.  
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PREFACE 
The United States spends about 17% of its gross domestic product (GDP) on healthcare, 
the most of any industrialized nation. Oncology care alone accounts for 5-10% of this 
expenditure(1). Although the cancer survival data in the US are better than for most 
industrialized nations, the fact that healthcare expenditure is rising faster than the GDP 
makes the current situation unsustainable. Many factors account for this dilemma, most 
of which are not under the direct control of the healthcare providers.  
  One area in which healthcare providers can be instrumental is cost effectiveness 
analysis, the lack of which has created an environment of evidential uncertainty. This 
leaves providers, payors, policy makers and patients confused when considering the best 
way to spend the limited resources available to achieve maximum quality care. The UK 
has attempted to solve this problem by creating the National Institute for Clinical 
Excellence (NICE), which is charged with evaluating the cost effectiveness of 
medications and medical procedures in deciding whether their use by patients is justified 
at the government’s expense (2) .Accordingly they have recommended against the use of 
some expensive oncologic medications that are commonly used in the United States due 
to lack of cost effectiveness. Examples of these include bevacizumab in combination with 
a platinum doublet (platinum compound combined with another chemotherapy 
medication) in metastatic non-small cell lung cancer. Similarly, the use of erlotinib as 
second line treatment for metastatic non-small cell lung cancer is only recommended on 
condition the manufacturer provides the drug at a cost comparable to that of docetaxel, 
which is regarded as standard second line therapy with comparable survival outcomes, 
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but costs far less.(3, 4). Other countries such as Australia and Canada have created 
regulatory agencies to control health care cost. In Australia, the Pharmaceutical Benefits 
Scheme (PBS) and in Canada the single payer system are charged with the responsibility 
of policing healthcare cost (6); (4). While we have a different health care system in the 
US, there is no reason why some of these concepts cannot be applied (6).  
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INTRODUCTION 
Worldwide lung cancer is the leading cause of cancer in males, accounting for 17% of all 
new cancer cases and 23% of all cancer deaths. In females it is the fourth leading cause of 
cancer death. In 2010 an estimated 1.6 million new cases of lung cancer were diagnosed 
worldwide with approximately 1.4 million deaths .In the same year, there were about 
374,000 lung cancer survivors in the USA and this number is expected to rise to 412,000 
by 2020(7). Furthermore, according to CDD data, in 2012, there were an estimated 202, 
000 new cases of lung cancer and 159,500 lung cancer deaths in the USA. Worldwide 
tobacco smoking accounts for about 80% of lung cancer in males and about 50% of lung 
cancer in females.  In the United States of America, smoking accounts for approximately 
90% of lung cancer cases. The economic impact of lung cancer is staggering not only 
because it is expensive to treat (the direct cost of cancer care in the USA was about $124 
billion in 2010 with lung cancer alone accounting for about 13% of all cancer 
expenditures), but because it also leads to premature death. The economic burden of 
premature death due to cancer in the USA is projected to reach $148 billion by 2020 and 
lung cancer alone will account for 27% of this. 
Though the United States cancer expenditure (mostly direct cost) constituted about 5% of 
total health care costs in 2010 which is comparable with figures from other industrialized 
nations, studies suggest that increases in costs of cancer treatment could begin to outpace 
health-care inflation as a whole, and become responsible for a rising percentage of total 
health-care spending.(8). Moreover, certain factors not properly taken into account when 
estimating cost of cancer care nonetheless play a role in the rising cost. These include 
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current cancer incidence, patterns of care, cancer survival and the escalation in the costs 
of cancer chemotherapy, which has outpaced general medical care inflation. For example, 
Mariotto, et al. argued that the National Institutes of Health (NIH) estimates of direct 
costs of cancer care at $91 billion were flawed because factors such as changes in 
incidence trend, survival and population demographics were not accounted for.  Using 
different methods developed specifically to account for these factors, the cancer-
associated cost was estimated to be $124.5 billion and $157.7 billion for 2010 and 2020 
respectively, representing a 27% increase when they accounted for population changes 
alone. When adjusted for a 2%/year increase in cost of care for the first and last years of 
life, the 2020 figure was $170 billion (37% increase). Lung cancer accounted for $12.12 
billion in 2010 and will account for $14.74 billion in 2020, second only to breast cancer.  
Based on Medicare’s SEER data, lung cancer care accounted for 20% of Medicare's total 
expenditures for cancer in 2008(9) .The estimated monthly cost of treating stage IV lung 
cancer (1992–2003) depended on the phase of treatment, ranging from about $12,000–
$16,600 in the staging (diagnosis and treatment planning) phase, $3,400–$9000 in the 
initial phase, $5,500–$11000 in the continuous phase, and $14000–$16500 in the 
terminal phase.(10)  
Important changes have taken place in the treatment of metastatic non-small cell lung 
cancer since this study was published. These include the use of platinum doublets, the 
increased use of targeted therapies and the shift in cancer chemotherapy administration to 
the outpatient setting. It is also likely that the use of imaging has increased. 
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What drives the cost of cancer care in the USA today?  
Figure 1 below is borrowed from the proceedings of a Lancet Oncology commission, and 
may help illustrate the difficulties in providing affordable cancer. 
 
Figure 1:  Classes of interventions to target for decreased utilization. 
The increase in the cost of cancer care in the USA today can be attributed to many 
factors, such as the cost of research & development and clinical trials especially in the era 
of personalized medicine (e.g. testing a lung tumor for the EGFR mutation costs 
approximately $400).  Fortunately, research and development has led to more effective, 
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though also more expensive therapies that provide significantly improved overall survival 
and in some cases fewer side effects when compared to cytotoxic chemotherapy 
commonly used in a majority of the patients today.  This increased survival and cost of 
medications ultimately leads to increased overall costs of care, although they may be 
more cost effective than cytotoxic chemotherapy in the long run. Given the high cost of 
these new therapies, their use for certain indications cannot always be justified especially 
when there are much cheaper alternative therapies that can provide generally similar 
outcomes. Other factors responsible for rising costs include current cancer 
incidence/prevalence as well as patterns of care. 
Several other reasons account for lack of cost effectiveness in the American health care 
system. The cost of healthcare administration in the US is high, accounting for 
approximately 30% of the entire healthcare budget compared to about 16% in Canada 
(11). The FDA only considers safety and efficacy and does not engage in economic 
analysis when evaluating medicines or healthcare technologies for approval. There is a 
lack of well-designed cost and cost effectiveness analysis studies. On the front lines of 
healthcare spending, oncologists and other providers do not necessarily consider cost 
analysis as part of the decision making process before recommending specific therapies. 
The last two factors in addition to the current physician reimbursement have led to the 
routine use of some expensive therapies by providers despite lack of evidence that these 
improve outcomes. For example, although GCSF-supported therapy has not been shown 
in randomized trials to either improve overall cancer survival or quality of life in patients 
with any of the four most common solid tumors (12) , Smith et al. found that its use as 
	  5 
supportive therapy in patients with these cancer types was prevalent and generated 
substantial profit to medical practices and to drug manufacturers. This study showed that 
in 2011 GCSF generated $1.25 billion per year in sales and provided substantial profits to 
large oncology practices in Northern California; the revenue earned from each dose of 
pegfilgrastim (Neulasta, Amgen) was 6% ($141) for Medicare patients, 25% ($611) from 
one of their larger commercial insurers, and 53% ($1,312) from another health plan (13). 
Patients and families may demand more care with unrealistic expectations for various 
reasons; providers may not have taken the time to educate them about their disease and so 
patients and families may lack the understanding of the disease process. They are likely 
unaware of the cost of the care they expect or care little about cost if they are not paying 
for it directly, hence pushing providers to deliver care at exorbitant prices and with 
marginal benefit.  
While patients with cancer do incur substantial additional costs during their treatment, 
which should be considered when making treatment decisions, this may not be obvious to 
the providers and or patients. For example, prior to a cancer diagnosis, health care costs 
for a 72-year-old patient increased by 20% over 10 years (1992-2003) while the costs for 
a typical cancer patient showed a 107% increase over the same period. A 72-year-old 
patient in 2000 receiving an active course of treatment for cancer incurred patient-share 
costs ranging from $899 to $2,004 per month, (15–22% of total health care costs), though 
not necessarily paid out-of-pocket if they have third party insurance. Given the increase 
in the cost of care, this figure is likely much higher today, particularly in lung cancer, 
where newer chemotherapeutic agents are much more expensive. The lack of early 
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incorporation of end-of-life discussion and involvement of palliative care consultation 
into the treatment paradigms for patients with advanced cancer have also contributed to 
the rising cost of cancer care. Patients and providers may avoid initiating end-of-life 
discussions due to fear that this will be perceived as surrender in the fight against cancer. 
In a prospective, multicenter study of 360 patients with advance stage cancer, only 37% 
of patients and their families could recall having a discussion about impending death with 
their physician (14). Patients with end-stage cancer likely receive treatment despite 
futility of such care. One study showed that about 20% of patients were given 
chemotherapy within the last 2 weeks of life and that the average time spent by lung 
cancer patients on hospice was only four days (15). About half of the total healthcare 
expenditures for cancer patients are in the inpatient setting. This suggests that efforts to 
increase the proportion of care delivered in the outpatient setting may reduce the cost of 
care, as some of the cost incurred in the inpatient setting could be avoided. 
The median survival of patients with metastatic non-small cell lung cancer without a 
targetable mutation is about 6 months without treatment and about 8-12 months with 
chemotherapy. There are several different chemotherapy regimens that have been shown 
to improve both overall survival and quality of life in this patient population. These 
include cytotoxic chemotherapy and targeted therapy. Most trials leading to the approval 
or recommendation of most of these regimens did not include an economic analysis. 
Though many of the regimens are comparatively effective, the price difference for both 
direct cost and the management of side effects can be substantial. 
While diagnostic imaging has generally been estimated to constitutes less than 6% of the 
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total oncology care cost in the past, its utilization has gone up quite significantly .The 
lack of evidence based guidelines on use of imaging during treatment of metastatic 
NSCLC contributes to high variability in use and excessive imaging by some, despite the 
lack of evidence correlating more frequent imaging with improved outcomes. Available 
data suggest that there is little or no benefit from imaging patients during treatment, 
except during select clinical decision points. More studies are needed to determine the 
best use of imaging in this patient population. The American Society of Clinical 
Oncology has put out guidelines aimed at reducing use of costly imaging in specific 
situations but practice is still highly variable.  
Increased treatment not only results in direct additional cost associated with the therapy 
but also may lead to more toxicity, hence increasing healthcare utilization through 
hospitalization (49 % of total cost), ER visits or outpatient clinic visits. 
What is considered cost effective in oncology care? 
The answer to this question may depend on who is asked the question, who pays the bills 
and when. Common perceptions suggest upper limits of good value (cost effective) care 
in general range from $50,000 per quality adjusted life year (QALY) to $100,000 per 
QALY. Experts suggest that these thresholds are probably too low, outdated, and might 
be contributing to resistance to cost-effectiveness analysis in the United States. As a 
result, some researchers and stakeholders have discussed updated thresholds for 
willingness to pay.  Current values for cost-effectiveness were first proposed in the 1970s 
and 1980s based on cost effectiveness of hemodialysis. Adjusting this value to 2007 USD 
equates to $197,000 per QALY. The World Health Organization’s suggested calculation 
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sets the threshold at $140,100 per QALY in 2008 USD. Other experts have suggested that 
the values be set at not more than threefold the per capita income of a country, which in 
the US will equate to about $150,000 USD. 
In 2006, Nadler et al. surveyed 139 medical oncologists at two academic hospitals in 
Boston as part of a cost effectiveness evaluation of bevacizumab and a hypothetical new 
cancer drug costing $70,000 per year and found that the majority of oncologists did not 
consider cost when deciding the choice of treatment for their patients as long as they 
deemed the treatment “effective.” The implied cost effectiveness threshold from the 
oncologists’ perspective in this study was over $300,000 USD/QALY, a far cry from 
current values of $50,000 USD/QALY commonly quoted today or the $130,000–
$197,000 USD/QALY if adjusted for inflation and other factors. Interestingly, the 
oncologists were more willing to consider the patients’ out–of –pocket cost in their 
ultimate recommendations. Physicians in this same study also indicated that they would 
be more willing to consider cost in 5 years, mainly because they perceived that growing 
costs would impose greater rationing of care. One could conclude from these responses 
that as long as a third party pays the bills and there is little threat of “rationing”, cost 
consideration is less of a priority for some oncologists.  Sadly the rising cost of care, 
which has outpaced the growth in GDP, has led to increased cost consciousness in the 
healthcare industry which may be what the physicians were describing as rationing of 
care. 
With these considerations in mind a retrospective study of the stage IV lung cancer 
patients treated at Boston Medical Center (BMC) between 2006 and 2011 was conducted. 
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The objectives of this study were to: (1) estimate the total institutional charges for 
treating stage IV non-small cell lung cancer patients and to identify drivers of cost in this 
patient population as well as the cost distribution; (2) estimate the difference in cost and 
survival between patients treated with cytotoxic chemotherapy only and those treated 
with targeted therapy at any point during their treatment, either alone or in combination 
with cytotoxic chemotherapy; and, (3) evaluate healthcare utilization cost and survival 
difference by patient demographics (gender, marital status, race, English language 
fluency, homelessness, and medical insurance status). 
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METHODS  	  
The Boston Medical Center cancer database was searched for all stage IV non-small cell 
lung cancer patients treated between 2006 and 2011. Two hundred and thirty -five 
patients matched this search. Eleven of these patients were eliminated from the study as a 
review of their records revealed that they were not properly characterized (1 patient had a 
diagnosis of lymphoma, 3 patients had stage III non-small cell lung cancer, 2 patients had 
stage IA NSCLC, 1 patient had esophageal cancer, 1 patient had metastatic colon cancer, 
1 patient had two primaries (pancreas and lung), and tissue biopsies were not available 
for 2 patients.). Hence in total there were two hundred and twenty-four patients included 
in the study. 
Demographic information was obtained for these patients including gender, age, race, 
marital status, smoking status, housing status and English language fluency. Histologic 
diagnosis and ECOG performance status at the start of therapy or at presentation were 
also obtained. 
The date of diagnosis was assumed to be the date the pathologist first read the lung 
biopsy specimen.  The date of the patient’s first visit to the oncology clinic was used as 
the starting point in estimating the outpatient charges. Patients who received 
chemotherapy and those who did not were identified, and the reasons for not receiving 
chemotherapy were documented.  
For the patients who received chemotherapy, the specific regimens and the number of 
cycles of chemotherapy each patient received were extracted from the medical records. 
The total number of clinic visits each patient attended during the course of their 
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treatment, including those clinic visits for which they did not receive chemotherapy were 
documented. 
Date of death for each patient was identified through the Social Security Administration’s 
Death Master File as well as relevant websites. 
From the records the number of computed tomography (CT) scans magnetic resonance 
imaging (MRI), positron emission tomography (PET) and bone scans performed on each 
patient from the date of diagnosis until death or censor were calculated. The number of 
inpatient hospital admissions and total number of days  spent in the hospital from date of 
diagnosis to death or  censor were  obtained from the records as well  as the number of 
ER visits for each patient.  These were then used to calculate the total inpatient and ER 
visit charges. These charges were provided by the patient financial office. Imaging 
charges (CT, MRI, PET scan, bone scan) were provided by the Radiology Department 
billing office. 
The cost of medication and drug administration charges were provided by the outpatient 
chemotherapy pharmacist. The oncology facility charges, provider charges and cost of 
laboratory tests were provided by the outpatient billing office. Pathology charges were 
provided by the Pathology Department billing office. 
The outpatient chemotherapy charges were calculated as the sum of the cost of 
medication (provider’s retail price), facility charges, charges for administering the drug 
(based on standard reimbursement depending on the duration of infusion), provider visit 
charge, and the cost of laboratory tests.  
For the purposes of this study, charges for biopsy from the Surgery Department were 
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inaccessible. 
 
The following assumptions were made: 
i) All hospital admissions, ER visits and imaging done from the time of diagnosis till 
death of patient or censor were assumed to be cancer related.  
 ii) Total ER charges were estimated based on the actual estimates per ER visit provided 
by the billing department multiplied by the number of ER visits because a majority of the 
billing for the individual visits was not found. 
iii) The charges for pathology where estimated based on the information provided by the 
lung pathologist and billing office. 
iv) Because the imaging charges were also highly variable (same procedures billed 
differently for different patients), the charges were estimated based on the unit price per 
specific study type in order to get more accurate and representative charges. 
  
Subsection One; Statistical Method 
We analyzed the data with SAS version 9.3 (SAS Institute, Inc., Cary, NC). 
Survival time was calculated as the duration from diagnosis date to date of death. Six 
patients were alive at the time of censor and 27 had unknown survival status. The 6 living 
patients were censored at 9/25/2012. The 27 patients with unknown survival status were 
assigned dates of death at the median survival time (151 days). For these 27 patients, date 
of death was calculated as 151 days after diagnosis date.  
Twenty-six patients are excluded from analysis for the following reasons: 
• 23 patients lived <30 days after diagnosis 
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• 2 patients had missing diagnosis dates 
• 1 patient had an inpatient cost of $2.4 million 
 
Independent variables included in survival analysis were age at diagnosis (<65 years vs. 
≥65 years), sex, race (white vs. non-white and unknown), English fluency, marital status, 
homelessness, smoking status, and treatment group (any biologic vs. no treatment, only 
cytotoxic vs. no treatment, and any biologic vs. only cytotoxic). A Cox regression model 
was created with backward elimination, starting with all independent variables and 
removing the variable with the highest p-value at each iteration until all variables 
remaining in the model had a p-value <0.10. 
Linear regression was used to assess predictors of cost per month of survival. Cost per 
month of survival was a continuous dependent variable. Independent variables were age 
at diagnosis (<65 years vs. ≥65 years), sex, race (white vs. non-white and unknown), 
English fluency, marital status, homelessness, smoking status, and treatment group. A 
multivariate linear regression model was created with backward elimination, starting with 
all variables, removing the variable with the highest p-value each iteration until all 
variables remaining in the model had a p-value <0.10. 
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RESULTS 
Within the study period, 224 patients were seen at Boston Medical Center for Stage IV 
lung cancer. Of the 224 patients seen at BMC for Stage IV lung cancer, 26 patients were 
excluded from the final analysis, 2 because diagnosis date was missing, 1 because of an 
inpatient cost ($2.4 million) that was more than 3 STD from the mean and 23 survived 
less than 30 days from diagnosis hence the final analysis was done on 198 patients  
Of the 198 patients included in the final analysis, 43% were minority, 57 % were whites 
and 11% were homeless. 43% of the patients were treated with pharmacotherapy while 
57 % of the patients did not receive any form of pharmacotherapy.  The median overall 
survival was 5 months amongst all patients included in the analysis, 7.8 months for 
patients treated with cytotoxic chemo only and 9.2 months for patients who received 
targeted therapy as part of their treatment.  See tables 1–4 below 
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Table 1: Patient Characteristics 
 All Patients After exclusions* 
 n=224 n=198 
Male 125 (56%) 110 (56%) 
Race – White 131 (58%) 113 (57%) 
Race – Black  69 (31%) 63 (32%) 
Race – Hispanic 12 (5%) 11 (6%) 
Race – Asian 8 (4%) 7 (4%) 
Race – Other/Unknown 4 (2%) 4 (2%) 
Smoking 195 (87%) 173 (87%) 
Homeless 21 (9%) 21 (11%) 
   
Treatment – only Cytotoxic  49 (22%) 48 (24%) 
Treatment – only Biologic 2 (1%) 2 (1%) 
Treatment – Cytotoxic and Biologic 35 (16%) 35 (18%) 
No Treatment – Neither Cyt nor Bio 138 (62%) 113 (57%) 
   
Alive at time of censor – Yes 6 (3%) 6 (3%) 
Alive at time of censor – No 191 (85%) 165 (83%) 
Alive at time of censor  – Unknown  27 (12%) 27 (14%) 
 
 Survival  
Survival 
  
Excluding 2 patients with missing diagnosis dates 
Excluding 23 patients who lived <30 days after diagnosis 
Excluding 1 patient with inpatient cost of $2.4 million 	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Table 2: Months of Survival at Death or Censor 
 n mean Median 
All 198 8.3 5.0 
Any chemo (cytotoxic and/or biologics) 
(groups 2, 3, 4) 85 9.5 7.8 
Biologics (with or without cytotoxic) 
(groups 2, 4) 37 10.6 9.2 
Cytotoxic without biologics 
(group 3) 48 8.6 7.0 
No chemo  
(group 1) 113 7.4 5.0 
NB: If alive, censor at 9/25/12. If unknown survival status, assume median survival time 
(diagnosis date + median survival). Median survival is 151 days. 
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Table 3: Charges 
 
  
Median charges in parenthesis Total charges with Estimated Imaging 
 n Mean Median P25 P75 
All 198 127,652 97,542 52,225 172,037 
Any chemo 
(cytotoxic and/or biologics) 
(groups 2, 3, 4) 
85 193,839 164,004 98,601 266,730 
Biologics 
(with or without cytotoxic) 
(groups 2, 4) 
37 258,562 247,251 164,005 301,634 
Cytotoxic without biologics 
(group 3) 
48 143,948 112,350 75,601 180,442 
No chemo 
(group 1) 
113 77,866 70,278 29,319 101,390 
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Table 4: Charges per Month with Estimated Imaging 
 n Mean Median P25 P75 
All 198 28,318 18,367 7,831 40,603 
Any chemo (cytotoxic 
and/or biologics) 
(groups 2, 3, 4) 
85 28,608 21,240 12,771 42,159 
Biologics  
(with or without cytotoxic) 
(groups 2, 4) 
37 32,877 25,853 13,283 45,760 
Cytotoxic without biologics 
(group 3) 
48 25,317 18,762 9,700 33,492 
No chemo 
(group 1) 
113 28,101 13,934 3,793 36,371 
 
Controlling for treatment type, the hazard ratio of death for white patients was 0.683 
relative to that of non-white patients and patients with unknown race, indicating that 
white patients were less likely to die compared to non–whites. 
 
Controlling for race, the hazard ratio for patients receiving treatment with only cytotoxic 
chemotherapy was 0.705 relative to that of patients not receiving pharmacotherapy, 
indicating that cytotoxic chemotherapy alone was associated with improved survival  
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Controlling for race, the hazard ratio for patients receiving treatment with targeted 
chemotherapy was 0.486 relative to that of patients not receiving pharmacotherapy, 
indicating that treatment with targeted chemotherapy was associated with reduced risk of 
death greater than with cytotoxic chemotherapy alone. 
 
Controlling for age at diagnosis, an increase of $1,000 in charges per month of survival is 
associated with an increase in the hazard by a factor of 1.024, implying that higher 
monthly charges was associated with increased risk of death.  
 
Controlling for charges per month of survival, patients 65 years or older had a hazard 
ratio of 1.365 that of patients younger than 65 years at diagnosis, implying that the risk of 
death was higher for older patients  
 
Controlling for homelessness, charges per month of survival for white patients is, on 
average, $12,305 less than for non-white patients and patients with unknown race.  
 
Controlling for race, charges per month of survival for homeless patients is, on average, 
$15,296 more than for non-homeless patients. 
 
 
 
 
 
 
 
	  20 
Figure 2. Mean charges distribution for all subjects in the study 
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DISCUSSION 	  
Between 2005 and 2011, 224 patients were evaluated at Boston Medical Center for stage 
IV non-small cell lung cancer, 23 patients died within 30 days of diagnosis; these were 
excluded from the analysis because most of the cost incurred by these patients was not 
for treating their cancer.  
 In total 43% were treated with pharmacotherapy; of whom 22% were treated with 
cytotoxic chemotherapy only, 1% were treated with targeted therapy only, 16% were 
treated with both cytotoxic and targeted therapy while 57% did not receive any form of 
pharmacotherapy for various reasons.  The percentage of patients who did not receive 
chemotherapy in this study is higher than figures from the National Cancer Data Base 
within the study period. The reason for this discrepancy is unclear. One reason may be 
that until recently patients with unresectable Non-small cell lung cancer including stage 
IIIB was classified as an advance stage disease, which will inflate the percentage of 
patients with real stage IV disease receiving chemotherapy. Another reason may be that 
our patient population is different. BMC treats a lot of underserved population, many of 
whom present to the provider not only with advanced disease but who also have multiple 
concurrent comorbidities, limited resources and in some case limited understanding of 
their disease, all of which may impact survival.  These factors may in many cases make 
the risk of chemotherapy outweigh the potential benefit; hence it is also possible that 
these providers did a good job at screening out the patients who did not stand to benefit 
from chemotherapy. It is also possible that some patients needing treatment did not 
receive it but this is beyond the scope of this study .The percentage of patients treated 
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with targeted therapy in this study was also smaller than would be expected currently as 
more targeted drug choices have become available and the laboratory testing to identify 
eligible patients has also improved and become more available. There is little 
contemporaneous data on use of targeted therapy in order to do a fair comparison.  
  The median overall survival was 8 months amongst all study participants treated with 
any form of pharmacotherapy compared to 5 months for those who did not receive any 
pharmacotherapy. Of the patients treated with pharmacotherapy, the median overall 
survival was as expected better for those who received biologics as part of their therapy 
compared to those who did not (9.2 months vs. 7 months). The number of patients treated 
with targeted therapy alone was too small to do an independent analysis.  
The survival data are similar to contemporaneous national survival data, which range 
from about less than 6 months for untreated patients to between 8 and 10 months for 
patients who received chemotherapy. Survival for this patient population (stage IV 
disease) should be better now given that a higher proportion of patients are treated with 
targeted therapies than during the period of the study.   It may not be unreasonable to 
expect some patients with non –small cell lung cancer with identifiable driver mutations 
treated with targeted therapy to survive more than three years today.  
Mean overall treatment charges at Boston Medical Center amongst all study participants 
was $127,652. For those who did not receive pharmacotherapy the mean overall 
treatment charges was $77,866 compared to $193,839 for those treated with any 
pharmacotherapy which is similar to published data.  As expected among those who 
received pharmacotherapy, the overall charges for treated patients were higher for those 
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treated with targeted therapy compared to those who were not ($258,562 vs. $143,948). 
Though the mean overall charges were higher for patients who received pharmacotherapy 
compared to those who did not, the mean monthly treatment charges were similar at 
about $28,000 owing to the inferior survival outcome among the untreated patients. 
Among those patients treated with pharmacotherapy, the mean monthly charges were 
lower for those who received cytotoxic chemotherapy only compared to those treated 
with targeted therapy alone or in combination with cytotoxic chemotherapy ($25,000 vs. 
$33,000).  
The charge distribution among all patients in the study showed the highest charges were 
incurred in the inpatient setting (56%), with imaging accounting for 23% of the total 
charges. Though the charge distribution was consistent with other published data, the 
percentage of inpatient charges in our study was higher (56% compared to 49% in some 
studies.  Furthermore the percentage of imaging as a function of the overall charges 
(23%) was higher in our study compared to published national estimates .An analysis of 
the data separated into untreated and treated patients showed that the percentage 
contribution of inpatient charges and imaging charges were significantly higher among 
untreated patients compared to treated to patients (69%, 26% vs. 43%, 23 %, 
respectively). Further breakdown of the outpatient charges for patients treated with 
chemotherapy showed that close to ¾ of the charges were for chemotherapeutic agents, 
with MD fees (both professional and facility), labs, chemotherapy administration cost and 
non-chemotherapy RN visit costs accounting for slightly more than ¼ of the total 
charges. This cost breakdown is very important as it will enable hospital policy makers to 
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better target and eliminate areas of waste within the section of hematology-oncology.   
Currently about 75% of non-small cell lung cancer patients have an identifiable driver 
mutation, though targeted therapy is yet to be developed for most of them. These 
advances are likely to increase certain components of the cost of care such as drug prices 
and cost of diagnosis (screening for driver mutation and other mitigating factors 
necessary for personalized treatment). These advances will likely also lead to increase 
survival, which means the overall cost of care per patient will increase. On the other 
hand, inpatient cost, and cost of chemotherapy administration, and probably cost of 
managing side effect may decrease.  With more patients treated with targeted therapy, the 
overall cost of treating stage IV lung cancer patients may likely increase but because 
survival is also improving, more side effects are prevented and patient /care giver time 
wasted is reduced to bare minimum, the cost effectiveness is expected to improve.  It is 
therefore expected that the cost distribution shown above may change significantly in the 
near future.  
The few studies that have been done in this field have either used different study 
characteristics (advanced lung cancer, elderly patients, total healthcare utilization, etc.) or 
different methodologies (mostly looking at the SEERS database or claims from HMO or 
insurance providers), making comparison difficult. Nevertheless, the estimated charges of 
treating stage IV non-small cell lung cancer at Boston Medical Center is similar to cost 
estimates from other published studies, although expenditure breakdown was different. 
For example, Vera-Llonch et al. estimated the mean cost of care for this patient 
population at $125,849 (study conducted between 2000–2006), but unlike this study and 
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other published studies, which show that in-patient expenditure accounts for the majority 
of the expenditure, their study suggested that out-patient expenditure accounted for the 
greater share of the cost. Yebroff et al. and Lang et al. put the estimate at about $85,000. 
Lang’s study excluded the cost of chemotherapy; however these two studies are 
consistent with this study’s finding that most of the expenditure is incurred in the 
inpatient setting. 
This study attempted to address certain predictors of survival and increased cost, which 
have rarely been addressed in previous studies with the following findings.  
From other studies, predictors of improved survival were white race (HR 0.68) and 
treatment with any form of chemotherapy (HR 0.70 with cytotoxic chemo and 0.49 with 
targeted therapy)   
Predictors of inferior survival outcomes were non-White race, patients who did not 
receive any pharmacotherapy, age older than 65 Years (HR 1.37) and homelessness. 
Marital and smoking status did not significantly affect the outcome. While it may be 
obvious why the elderly and the untreated patients have inferior outcomes, the rationale 
for superior outcome among Whites compared to non-Whites was not so clear. It is not 
clear whether it is due to the difference in biology of disease as reported in some other 
cancer types or disparity in care. Despite the inferior survival amongst the minority 
patients, the White patients were on average charged $12,305 less than their non-White 
counterparts. The charges per month of survival were on average $15,296 higher for 
homeless patients compared to those who were not homeless, possibly due to higher 
health services utilization such as prolonged inpatient stay and ER visits. Finally higher 
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monthly charges were associated with increased risk of death (HR 1.024 per $1000 
increase in average monthly charges).  We were unable to find any published studies on 
predictors of cost and survival to compare our study’s findings. Results from this study 
suggest that this to be a relevant research area as this will help in resource allocation. 
Most studies have not separated the cost distribution into patients who received 
chemotherapy and those who did not. From this study the percentage of inpatient cost is 
even higher (70%) for patients who did not receive chemotherapy. 
This separation is important because treatment goals are different and may enable stake- 
holders to better allocate scarce resources.  For example, the BMC and similar 
institutions with robust geriatric programs could develop creative ways of minimizing the 
amount of time spent in the hospital by elderly patients with terminal cancer who are not 
candidates for chemotherapy. One such program may include early transition to the 
geriatric home care program with a periodic oncologist home visits or phone calls. This 
will offer support and allow the patient and family not feel “abandoned” by their 
oncologists.  This may be especially useful to the group of patients who are reluctant to 
consider hospice or outpatient palliative care as an option.   Early involvement of the 
palliative care has been shown not only to improve patients’ quality of life but also to 
improve survival and in some cases reduced cost of care. One could deduced from the 
significant expenditure incurred by patients in the inpatient setting as well as the high 
percentage of patients who did not receive chemotherapy in this study that probably early 
involvement of palliative care and or hospice care may have been beneficial both patients 
and the healthcare system.  If similar studies are reproduced at other institutions, it may 
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go a long way to not only compare survival data from various institutions, but more 
importantly, compare the cost of treatment necessary to achieve reported survival at 
different institutions. An efficiency index may then be developed incorporating patient 
survival, cost of care, patient’s quality of live among other measures to better assess 
performance of different healthcare providers and institutions. 
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The limitations of our studies were the following; 
i) The sample size for this study was small which may make the interpretation of the P 
value and confidence interval difficult. Hence it is entirely possible that if there was a 
larger sample size, some of the variables that were included in this analysis like smoking, 
marital status etc. might have shown different results.  The fact that this study was 
conducted at a single institution also makes it less generalizable.  
ii) This study is retrospective in nature with all inherent limitations of retrospective 
studies; we were only able to work with data documented in the system, some of which 
was missing. We also had to assume that all the recorded data was accurate but as evident 
by the one patient whose inpatient charges were more than 3SD from the mean, it is 
possible that some of the data could have been wrongly entered, which will affect the 
validity of our results. Being a retrospective study, we could only show an association 
between variables and not cause and effect. Examples include association between white 
race and lower charges per month of survival, homelessness and higher charges per 
month of survival as well as higher charges and inferior survival. Whether there was a 
cause and effect is not clear.  
iii) Some of the charges had to be estimated because the actual charges could not be 
found; this was especially true for ER visits with less than 30% of the billing data 
available; meanwhile not only was some of the billing data for imaging missing but in 
some circumstances there was also a lot of discrepancy in the billing; for example there 
were many cases where patients were charged different amounts for the same type of 
imaging, sometimes as much as 3-4 times. This reduces the precision or power of our 
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results.  
iv)  Charges were used as a surrogate for actual cost but charges do not necessarily 
translate to actual cost (the amount paid to the hospital) because different insurance 
companies pay different rates which make it very difficult to estimate actual cost of 
treatment. For example MEDICARE pays about 31 cents on the dollar at BMC, 
MEDICAID about 21 cents on the dollar while the major commercial companies pay 
between 39 cents to 49 cents on the dollar as of 2013, however these figures were 
different for each year within the study period.  
Despite these limitations this study is very useful as it may enable the section of 
Hematology /oncology at BMC, where the study was conducted, to eliminate waste and 
reallocate resources to more specifics areas likely to yield better outcomes. If these 
studies are replicated in all institutions around the country, then it will allow stake 
holders to be able to compare not only outcomes like survival but also cost effectiveness.  
Though there are several quality measures including currently in use to compare cancer 
care across different institutions, the most commonly used in oncology today is survival 
data. This may be a flawed comparison because of the discrepancy in patients 
characteristics treated by different institutions and the difference in resources utilization 
is not always accounted for hence making it difficult to reliably evaluate efficiency across 
institutions. In this era of cost consciousness these types of studies will be very useful to 
policy makers, payors and patients in making informed choices about where to seek 
quality care. It also helps providers to compare the cost effectiveness of the care they 
provide their patients with other institutions. 
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APPENDIX 
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Outcome: Survival Time	  	  
	  
All  (n=198) 
 
Log Rank Test 
 
 
 
 
 
 
	  
	  
	  
	  
	  
	  
	  
	  
	  
Cox Regression1 
	  
	  
	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1 Backwards elimination, starting with all variables, removing the variable with the highest p-
value each iteration until all variables remaining in the model have a p-value <0.10.  
Variable Chi-Square P-value 
Age at diagnosis (<65 years vs. ≥65 years) 3.29 0.07 
Sex 0.32 0.57 
Race 2.01 0.16 
English Fluency 0.0005 0.98 
Marital Status 0.10 0.75 
Homelessness 0.25 0.62 
Smoking 1.86 0.17 
Any Biologic vs. No Treatment (n=150) 8.49 0.0036 
Only Cytotoxic vs. No Treatment (n=161) 2.27 0.13 
Any Biologic vs. Only Cytotoxic  (n=85) 2.92 0.09 
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Outcome: Survival Time 
Treated (n=85) 
 
Log Rank Test  
	  
Variable Chi-Square P-value 
Age at diagnosis (<65 years vs. ≥65 years) 0.38 0.54 
Sex 0.25 0.62 
Race 0.43 0.51 
English Fluency 1.28 0.26 
Marital Status 0.0000 0.9969 
Homelessness 0.42 0.52 
Smoking 0.66 0.42 
Any Biologic vs. Only Cytotoxic  2.92 0.09 
	  
	  
	  
Cox Regression2 
	  
	  
	  
	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
2 Backwards elimination, starting with all variables, removing the variable with the highest p-
value each iteration until all variables remaining in the model have a p-value <0.10.	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Outcome: Survival Time 
Untreated (n=113) 
 
Log Rank Test  
 
Variable Chi-Square P-value 
Age at diagnosis (<65 years vs. ≥65 years) 1.58 0.21 
Sex 0.07 0.79 
Race 5.98 0.01 
English Fluency 4.29 0.04 
Marital Status 0.04 0.85 
Homelessness 0.13 0.72 
Smoking 1.35 0.24 
	  
	  
	  
Cox Regression3 
	  
	  
	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
3 Backwards elimination, starting with all variables, removing the variable with the highest p-
value each iteration until all variables remaining in the model have a p-value <0.10.  
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Outcome: Survival Time 
Including cost per month of survival time 
Cox regression 
Only cost per month of survival as predictor of survival time 
	  
	  
	  
	  
Cox regression 
Multivariate model 4 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
4 Backwards elimination, starting with all variables, removing the variable with the highest p-
value each time until all variables remaining in the model have a p-value <0.10.	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Outcome: Cost per Month of Survival (estimated imaging) 
 
Treatment types (n=198) 
 
Univariate 
 
Variable β estimate P-value 
Any Biologic vs. No Treatment (n=150) 4777 0.49 
Only Cytotoxic vs. No Treatment (n=161) -2783 0.65 
Any Biologic vs. Only Cytotoxic  (n=85) 7560 0.15 
 
Multivariate model of three treatment types (dummy variables) is not significant. 
 
	  
	  
	  
	  40 
Outcome: Cost per Month of Survival (estimated imaging) 
 
All (n=198) 
 
Univariate 
 
Variable β estimate P-value 
Age at diagnosis (<65 years vs. ≥65 years) -3622 0.45 
Sex 5896 0.22 
Race -12615 0.01 
English Fluency -5445 0.43 
Marital Status 2251 0.65 
Homelessness 15942 0.04 
Smoking 6563 0.36 
Any Biologic vs. No Treatment (n=150) 4777 0.49 
Only Cytotoxic vs. No Treatment (n=161) -2783 0.65 
Any Biologic vs. Only Cytotoxic  (n=85) 7560 0.15 
 
Multivariate model5 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
5 Backwards elimination, starting with all variables, removing the variable with the highest p-
value each iteration until all variables remaining in the model have a p-value <0.10. 
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Outcome: Cost per Month of Survival (estimated imaging) 
 
Treated (n=85) 
 
Univariate 
 
Variable β estimate P-value 
Age at diagnosis (<65 years vs. ≥65 years) -3420 0.51 
Sex -3525 0.50 
Race -5564 0.28 
English Fluency -985 0.89 
Marital Status -3736 0.48 
Homelessness -1676 0.84 
Smoking -1831 0.81 
Any Biologic vs. Only Cytotoxic 7560 0.15 
 
	  
	  
 
 
 
Outcome: Cost per Month of Survival (estimated imaging) 
 
Untreated (n=113) 
 
Univariate 
 
Variable β estimate P-value 
Age at diagnosis (<65 years vs. ≥65 years) -3819 0.62 
Sex 13509 0.08 
Race -19174 0.01 
English Fluency -10190 0.39 
Marital Status 6949 0.38 
Homelessness 31580 0.01 
Smoking 13129 0.25 
 
Multivariate model6 
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
6 Backwards elimination, starting with all variables, removing the variable with the highest p-
value each iteration until all variables remaining in the model have a p-value <0.10.  
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All	  data	  included	  (n=224)	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 2000-2001 H. pylori and Peptic Ulcer disease in Western Nigeria:   
  Edmund Folefac, MD, A. Agwakuru, MD 
 
 2006 -2007 Developing Standard Criteria for bone marrow biopsy;  
  Kasia Gilek-Seibert, MD, Edmund Folefac, MD, Joseph  
  Jacobson, MD, R. Hasserjian, MD PhD, Abner Louissaint, MD,  
  PhD, James Stahl, MD,  
 
 10/12-10/13 Cost analysis and cost distribution in the treatment of metastatic  
  Non small cell lung cancer At Boston Medical Center. Edmund  
  Folefac, MD; Ken Zaner MD , PhD 
 
 9/12-present  Determining adult sickle cell population eligible for mini allo- 
  stem cell transplantation in the Boston area. Edmund Folefac, 
  MD, Duyen Ngo, MD  
   
 7/13-6/14 Research year at the Boston VA  
 
 
Publications                           
        
 2008 Reference Physiologic Ranges for Serum Biochemistry among  
  Cameroonians to Support HIV Vaccine and Related Clinical  
  Trials African Journal of Health Sc.   KEMRI/LIB/9/21, 2008    
  G. A. Alemnji, Ph.D., E. Folefac, MD, G. Teto, M.Sc,  
  Nkengafac, N. Atems, M.D, B. B.W. Kwingwah, M.D, J.  
  Mbuagbaw, MD T Asonganyi S. PhD 
 
 2012 Evaluating Expression of P53 as Genetic Modifiers of  
  Therapeutic Response in Stage IV Non-Small Cell Lung Cancer  
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  (abstract submitted to American journal clinical pathology)  Hao  
  Wu, MD PhD, Wei Guo, MA ,MS MPH, Edmund Folefac MD,  
  Ken Zaner, MD, Antonio de las Morenas, MD 
 
Poster presentation 
 
 10/08 Reference Physiologic Ranges for Serum Biochemistry among  
  Cameroonians to Support HIV Vaccine and Related Clinical  
  Trials. World AIDS conference, Cape Town, South Africa   
 
  5/2011 Childhood group B Beta hemolytic infection and Fronto- 
  Temporal dementia;  American Society of Geriatrics, . 
 
 
Journal review  
 
 2012-present Reviewer for PLoS One  
 
